|Slideshows|October 13, 2016

4 Warning Signs of Illness Falsification

Medical, psychiatric, and/or developmental disorders can be falsified in a variety of ways. Know the warning signs often missed by clinicians.

To view the information in PDF format, click here.

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Psychiatry and the Treatment of Stuttering: A Blossoming Partnership

ByMike Hennessy Jr

August 11th 2026

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

ByGerald A. Maguire, MD,Heidi Anne Duerr, MPH,Shahriar SheikhBahaei, PhD,Yoshikazu Kikuchi, MD, PhD,Lisa LaSalle PhD, CCC-SLP,Thomas J. Valente, MD,Anelise Junqueira Bohne, PhD, SLP,Tiago Proença dos Santos, MD,Gonçalo Leal, SLP,Devin Binder, MD, PhD,Gustavo Alva, MD, DFAPA,Greg Mattingly, MD

August 10th 2026

Podcast: Navigating Trauma, Transformations, and Truth With Emily Lafferman, MD

ByFrank A. Clark, MD,Emily Lafferman, MD

August 5th 2026

Attachment-Based Therapy in Adolescent Substance Users: A Meta-Synthesis of Emotional Isolation and Avoidant Attachment Patterns

ByBahareh Mahooti

July 28th 2026

Requiring AI-Driven Suicide Risk Stratification in Emergency Settings: Helpful or Risky?

BySarah Cheema, MD,Andrew Canto, MD,Nicolas Badre, MD

July 21st 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

4 Warning Signs of Illness Falsification

Related Content

Psychiatry and the Treatment of Stuttering: A Blossoming Partnership

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

Podcast: Navigating Trauma, Transformations, and Truth With Emily Lafferman, MD

Attachment-Based Therapy in Adolescent Substance Users: A Meta-Synthesis of Emotional Isolation and Avoidant Attachment Patterns

Requiring AI-Driven Suicide Risk Stratification in Emergency Settings: Helpful or Risky?

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Experience With Xanomeline/Trospium in an Acute Inpatient Setting Treating Individuals With Schizophrenia

Resuscitating the Biopsychosocial Model in Psychiatry

FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease

DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial

Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety